ORAL FORMULATION COMPRISING BIGUANIDE AND AN ORGANIC ACID

Abstract: An oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness.

Description: DESCRIPTION ORAL FORMULATION COMPRISING BIGUANIDE AND AN ORGANIC ACID TECHNICAL FIELD The present invention relates to an oral fomulation comprising a biguanide and an organic acid. BACKGROUND OF THE INVENTION Biguanides such as metformin have unpleasant tastes such as bitterness and saltiness. The dosages of metformin are about 250 mg per dose in Japan and about 850 mg per dose in United States of America. In spite of such big dosages, only tablets are on sale at present. There are several known methods for masking bitterness of bitter drugs, for instance, for solid formulations, sugar coated tablets, film coated tablets, capsules and the like are useful. Powders, fine granules and granules are formulated with sweetening agents or flavors; microcapsules, non-enteric coated formulation, spray-dried formulation with low melting point wax, formulation with lecithin (JP 62-265234-A) and the like may also be used. For solutions, there are formulations with water-insoluble high molecular weight compound such as ethylcellulose and hydroxypropylmethylcellulose phthalate (JP 52-41214-A); formulations with acidic phosphol ipids or lyso-phosphol ipids (JP 7-67552-A) ; and formulations with a large amount of citric acid (JP 4-58452-B). DISCLOSURE OF THE INVENTION The inventors of the present invention have intensively carried out research, and found that an oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness. Thus, the present invention has been accompl ished. The present inventions includes: [1] An oral formulation comprising a biguanide and an organic acid. [2] An oral formulation comprising a biguanide, an organic acid and a sweetening agent. [3] An oral formulation according to [1] or [2] wherein the biguanide is metformin or a pharmaceutical salt thereof. [4] An oral formulation according to any one of [1] to [3] wherein the organic acid is malic acid, citric acid, tartaric acid or mixture thereof. [5] An oral formulation according to any one of [1] to [4] wherein the sweetening agent is aspartame , saccharine, saccharine sodium, stevioside or mixture thereof. [6] An oral formulation according to any one of [1] to [5] wherein the ratio (w/w) of the biguanide to the organic acid is 1 : 0.01 to 1 : 50. [7] An oral formulation according to any one of [2] to [6] wherein the ratio (w/w) of the biguanide to the sweetening agent is 1 : 0.001 to 1 : 10 [8] An oral formulation according to any one of [1] to [7] wherein the formulation is solution, jelly, gum drops, dry syrup, powders, fine granules or granules. [9] An oral formulation according to any one of [1] to [8] wherein the pH of the solution is 3.5 to 6 in case that the formulation is solution, and the pH of the solution which is formed by dissolving or dispersing the formulation to 10 times more (w/w) volume of water, is 3.5 to 6 in case that the formulation is not solution. DETAILED DESCRIPTION OF THE INVENTION "Biguanide" includes compounds having a biguanide structure such as metformin, buformin, fenformin and pharmaceutically acceptable salts thereof. "Organic acid" includes malic acid, citric acid, tartaric acid, ascorbic acid, succinic acid, fumaric acid, maleic acid, gluconic acid, glucuronic acid and mixtures thereof. Preferable organic acids are organic acids having 2 or 3 carboxyl groups such as malic acid, citric acid and tartaric acid, more preferably malic acid. The ratio (w/w) of the biguanide to the organic acid is, for example, 1 : 0.01 to 1 : 50, preferably 1 : 0.02 to 1 : 10, more preferably 1 : 0.05 to 1 : 1. In the case of malic acid, the preferable ratio (w/w) of the biguanide to malic acid is 1 : 0.05 to 1 : 0.5. "Sweetening agent" includes aspartame , saccharin, saccharin sodium, stevioside, sorma tin, erythritol, sorbitol, xylitol, glycerin and mixtures thereof. Preferable sweetening agents are aspartame , saccharin, saccharin sodium and stevioside. The ratio (w/w) of the biguanide to the sweetening agent is, for example, 1 : 0.001 to 1 : 10, preferably 1 : 0.02 to 1 : 1. When the formulation is a solution, preferably the pH of the solution is 3.5 to 6, more preferably 4 to 6, to decrease the unpleasant tastes and to keep the biguanide stable. If the formulation is not a solution, the preferable pH of the solution or 4 dispersion which is formed by dispersing the formulation in water (1 part of the formulation to 10 parts of water, by weight), is 3.5 to 6, more preferably 4 to 6; This is in order to decrease the unpleasant tastes and to keep the biguanide stable. "Oral formulation" includes solution, jelly, gum drops, dry syrup, powders, fine granules and granules. Preferably the formulation is not in the form of tablets. The formulation of the present invention may include pharmaceutically acceptable non-toxic and inactive additives. Additives include excipients such as corn starch, potato starch, white sugar, mannitol, xylitol, sorbitol, talc, kaolin, calcium monohydrogen phosphate, calcium sulfate, calcium carbonate, crystalline cellulose; lubricants such as magnesium stearate and potassium stearate; disintegrators such as carboxymethylcel lulose calcium and low substituted hydroxymethylcel lulose; binders such as hydroxypropy1 eel lulose, hydroxypropylmethylcel lulose, polyvinypyrrol idone, gelatin, methylcel lulose, Arabia gum and polyvinylalcohol ; coloring agents; correctives; adsorbents; preservatives; stabilizers; moistening agents; de-charging agents; pH adjusters; and the like. The formulation may include flavors such as lemon, orange, grapefruit, pine, banana, chocolate and yogurt to decrease the unpleasant tastes more. The formulation of the present invention can be prepared by well known methods. In the case of solid formulations, the formulation can be prepared, for example, by extruding granulation 5 methods, crushing granulation methods, dry granulation methods, fluidized bed granulation methods, tumbling granulation methods, high shear mixing granulation methods, wet compression methods, direct compression methods and the like. The formulation of the present invention will contain the conventional amounts of active ingredient (biguanide) and will be used in conventional manner to administer doses in accordance with normal practice by routes and according to dosage regimes which are familiar to pharmacologists and medical practitioners. The present invention will be described in detail below, referring to Examples and Experiments, which are not limitative of the present invention. Example 1 Solution of metformin hydrochloride Ingredient weight % Ό Metformin hydrochloride 5 % Malic acid 0.8 % Aspartame™ 0.3 % Lemon flavor 0.1 % Purified water 93.8 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, aspartame and lemon flavor into purified water. Example 2 0 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Malic acid 0.8 % Saccharin sodium 1 % Lemon flavor 0.1 % Purified water 93.1 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharine sodium and lemon flavor into purified water. Example 3 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Citric acid 2 % Aspartame™ 0.3 % Lemon flavor 0.1 % Purified water 92.6 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, citric acid, aspartame and lemon flavor into purified water. Example 4 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Malic acid 1.5 % Saccharin sodium 0.25 % Erythritol 10 % Lemon flavor 0.1 % Purified water 83.15 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharin sodium, erythritol and lemon flavor into purified water. Example 5 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Mai ic acid 1.5 % Aspartame 0.2 % Sorbitol 6 % Grapefruit flavor 0.1 % Purified water 87.2 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, aspartame , sorbitol and grapefruit flavor into purified water. Example 6 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % o Malic acid 1.5 % Saccharin 0.03 % Glycerin 10 % Lemon flavor 0.1 % Purified water 83.37 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharin, glycerin and lemon flavor into purified water. Example 7 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Malic acid 1.5 % Saccharin sodium 0.25 % Saccharin 0.03 % Lemon flavor 0.1 % Purified water 93.12 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride, malic acid, saccharin sodium, saccharin and lemon flavor into purified water. Example 8 Dry syrup of metformin hydrochloride Ingredient Amount Metformin hydrochloride 500 g Malic acid 80 g Saccharin sodium 25 g Erythritol 865 g Polyvinylpyrrol idone K30 30 g Total 1500 g Metformin hydrochloride, malic acid, saccharin sodium, erythritol and polyvinylpyrrol idone K30 are mixed with 200 g of mixture of purified water and ethanol (1 : 1 (w/w)) to give wet solid. 33 % Dry syrup of metformin hydrochloride is prepared by milling the wet solid with a granulation mill to adjust the size of the granules, followed by drying. Example 9 Jelly of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Gelatin 0.5 % Malic acid 0.8 % Aspartame™ 0.3 % Lemon flavor 0.1 % Purified water 93.3 % Jelly of metformin hydrochloride is prepared by dissolving or dispersing metformin hydrochloride, malic acid, aspartame and lemon flavor into gelatin solution which is made by dissolving gelatin to purified water over 80 °C, followed by cooling. Example 10 Fine granules of buformin hydrochloride Ingredient Amount Buformin hydrochloride 100 g Mannitol 300 g Lactose 300 g Corn starch 150 g Malic acid 90 g Aspartame 30 g Methylcel lulose 30 g Total 1000 g Buformin hydrochloride, mannitol, lactose, corn starch, malic acid, aspartame and methylcel lulose are mixed with 200 g of purified water to give wet solid. 10 % Fine granules of buformin hydrochloride are prepared by granulating the wet solid with a basket granulation mill, followed by drying. Example 11 Gum drops of buformin hydrochloride Ingredient Amount Buformin hydrochl oride 100 mg Gelatin 600 mg Citic acid 100 mg Saccharin sodium 25 mg Sorbitol 1550 mg Lemon flavor 25 mg Purified water 600 mg Total 3000 mg Gum drops of buformin hydrochloride are prepared by dissolving or dispersing buformin hydrochloride, citric acid, saccharin sodium, sorbitol and lemon flavor into gelatin solution which is made by dissolving gelatin to purified water over 80 °C, followed by molding the mixture and cooling. Example 12 Powders of buformin hydrochloride Ingredient Amount Buformin hydrochloride 100 mg Mannitol 560 mg Corn starch 200 mg Citric acid 100 mg Aspartame 30 mg Magnesium stearate 10 mg Total 1000 mg 10 % powders of buformin hydrochloride are prepared by mixing buformin hydrochloride, mannitol, corn starch, citric acid, aspartame and magnesium stearate. Example 13 Solutions of metformin hydrochloride at various pH Using the same amount of each ingredient of Example 1, 5 % solutions of metformin hydrochloride at various pH are prepared by dissolving or dispersing metformin hydrochloride, malic acid, aspartame and lemon flavor into about 80 % of purified water, followed by adjusting pH of the solution to pH 2, 3, 3.5, 4, 5 or 6 using dilute hydrochloric acid or dilute sodium hydroxide solution and adding more purified water. Reference example 1 Solution of metformin hydrochloride Ingredient weight % Metformin hydrochloride 5 % Purified water 95 % 5 % Solution of metformin hydrochloride is prepared by dissolving metformin hydrochloride into purified water. Experiment 1 Tasting experiment Tasting experiments on the solutions of Examples 1 to 3 and Reference example 1 were carried out with 20 panelists. The numbers of panelists who felt the solution "not bitter", "a little bitter" and "very bitter" are shown in Table 1. Table 1 Solution "not bitter" "a little bitter" "very bitter" Example 1 11 8 1 Example 2 10 9 1 Example 3 11 8 1 Reference example 1 0 2 18 Tasting experiments on the solutions of Examples 4 to 7 were also carried out, with satisfactory results. Experiment 2 Tasting and stability experiments Tasting and stability experiments on the solutions at various pH of Example 13 were carried out, in the same manner as Experiment 1. A stability experiment was carried out by measuring the remaining amount of metformin in the solutions with HPLC after heating the solutions in vials at 60 °C for 2 weeks. The results are shown in Table 2. Table 2 pH taste remaining amountrø 2 very sour 78 3 sour 86 3.5 good 94 4 good 96 5 good 98 6 good 100 7 very bi tter 98 Metformin hydrochloride is not stable below pH 3.5, and the solution tastes sour. The solution over pH 7 has bitterness. Normally we feel bitterness most in solution formulation. Therefore these experiments on the solutions indicate that other formulations such as jelly, gum drops, dry syrup, powders, fine granules and granules have less unpleasant tastes as well. 14 The present invention provides an oral formulation of biguanide with less unpleasant tastes. With this invention, people in every age group, for example, elderly people and little children can easily have sufficient amount of biguanide.

Claims: 15 CLAIMS 1. An oral formulation comprising a biguanide and an organic acid. 2. An oral formulation comprising a biguanide, an organic acid and a sweetening agent. 3. An oral formulation according to Claim 2 wherein the sweetening agent is selected from aspartame , saccharine, saccharine sodium, stevioside and mixtures thereof. 4. An oral formulation according to Claim 2 or Claim 3 wherein the ratio (w/w) of the biguanide to the sweetening agent is 1 : 0.001 to 1 : 10 5. An oral formulation according to any one of Claims 1 to 4 wherein the biguanide is metformin or the pharmaceutical salt thereof. 6. An oral formulation according to any one of Claims 1 to 5 wherein the organic acid is selected from malic acid, citric acid, tartaric acid and mixtures thereof. 7. An oral formulation according to any one of Claims 1 to 6 wherein the ratio (w/w) of the biguanide to the organic acid is 1 : 0.01 to 1 : 50. 8. An oral formulation according to any one of Claims 1 to 7 in the form of a solution, jelly, gum drops, dry syrup, powders, fine granules or granules. 9. An oral formulation according to Claims 8 which is in the form of a solution wherein the pH of the solution is 3.5 to 6. 10. An oral formulation according to Claims 8 which is not in the form of a solution and the pH of the solution or dispersion which is formed by dispersing 1 part of the formulation in 10 parts 16 by weight of water is 3.5 to 6.

Inventors: KOBAYASHI HIROHISA, NISHII HIROYUKI, OTODA KAZUYA, KOBAYASHI, HIROHISA, NISHII, HIROYUKI, OTODA, KAZUYA
Applicants: KOBAYASHI HIROHISA, NISHII HIROYUKI, OTODA KAZUYA, SUMITOMO PHARMA, KOBAYASHI, HIROHISA, NISHII, HIROYUKI, OTODA, KAZUYA, SUMITOMO PHARMACEUTICALS CO., LTD.
Application year: 1999
Main classification: A61K31
IPC codes: A61K9, A61K31, A61K47